Durable response to pralatrexate for aggressive PTCL subtypesAugust 15, 2018Lymphoma & Plasma Cell DisordersPatient & Survivor Care
New myeloma drugs improve response and extend survivalAugust 15, 2018Lymphoma & Plasma Cell DisordersPatient & Survivor Care
Immunotherapies shape the treatment landscape for hematologic malignanciesAugust 15, 2018Lymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, TransplantationImmunotherapy
Lenalidomide becomes standard of care for multiple myeloma in the maintenance settingAugust 2, 2018Lymphoma & Plasma Cell Disorders
CAR T-cell approvals: multiple myeloma likely next upJune 21, 2018Lymphoma & Plasma Cell DisordersPatient & Survivor Care
2017 notches up some landmark approvalsMay 14, 2018Breast CancerLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Demystifying the diagnosis and classification of lymphoma: a guide to the hematopathologist’s galaxyApril 1, 2017Lymphoma & Plasma Cell DisordersPatient & Survivor Care
Unicentric Castleman disease disguised as a pancreatic neoplasmDecember 22, 2016Lymphoma & Plasma Cell DisordersPatient & Survivor Care
A look at HIV-related cancers: incidence, screening, and stem transplantationNovember 22, 2016Lymphoma & Plasma Cell DisordersPatient & Survivor Care
Split-dose R-CHOP: a new approach to administer cytotoxic chemo-immunotherapy to elderly patients with DLBCLNovember 22, 2016Lymphoma & Plasma Cell DisordersImmunotherapy
Outcome of tumor lysis syndrome in pediatric patients with hematologic malignancies – a single-center experience from PakistanNovember 22, 2016Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPatient & Survivor Care
Central nervous system manifestations of multiple myeloma: risk and prognostic considerationsNovember 21, 2016Lymphoma & Plasma Cell DisordersPatient & Survivor Care
Elotuzumab and ixazomib join the therapeutic arsenal for multiple myelomaAugust 24, 2016Lymphoma & Plasma Cell DisordersPatient & Survivor Care
